Floatz logo

Therapeutic Asset Ratings

6,305 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
rp-008
Trigeminal Neuralgia
Kriya Therapeutics, Inc.P1/2CC (47)
rtx001
Cirrhosis Of Liver
Resolution Therapeutics LimitedP1/2CC (47)
rtx001
Liver Disorder
Resolution Therapeutics LimitedP1/2CC (47)
s227928
Chronic Myelomonocytic Leukemia
Servier Bio-Innovation LLCP1/2CC (47)
s241656
Lung Cancer
Institut de Recherches Internationales ServierP1/2CC (47)
Sacituzumab Tirumotecan
Esophageal Cancer
Merck Sharp & Dohme LLCP1/2CC (47)
Sacituzumab Tirumotecan
Gastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLCP1/2CC (47)
Sacituzumab Tirumotecan
Urothelial Carcinoma
Merck Sharp & Dohme LLCP1/2CC (47)
sar444200
Neoplasm
SanofiP1/2CC (47)
sar444836
Phenylketonuria
SanofiP1/2CC (47)
Sarilumab
Metastatic Neoplasm
University of Southern CaliforniaP1/2CC (47)
Saruparib
Squamous Cell Lung Carcinoma
AstraZenecaP1/2CC (47)
sbt6050
Colorectal Cancer
Silverback TherapeuticsP1/2CC (47)
sbt6050
Gastric Cancer
Silverback TherapeuticsP1/2CC (47)
sc0191
Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.P1/2CC (47)
Scm-010
Secondary Progressive Multiple Sclerosis
Stem Cell Medicine Ltd.P1/2CC (47)
Sctb14
Cancer
Sinocelltech Ltd.P1/2CC (47)
Sctb41
Cancer
Sinocelltech Ltd.P1/2CC (47)
Selinexor
IDH-Wildtype Glioblastoma
National Cancer Institute (NCI)P1/2CC (47)
Selinexor
Marginal Zone Lymphoma
Barbara Ann Karmanos Cancer InstituteP1/2CC (47)
Semaglutide
Interstitial Lung Disease
University of PennsylvaniaP1/2CC (47)
sg001
Metastatic Neoplasm
Shanghai Runshi Pharmaceutical Technology Co., LtdP1/2CC (47)
Shb-02-Cd19
B-Cell Neoplasm
Sheba Medical CenterP1/2CC (47)
Shr-A2102 For
Non-Small Cell Lung Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.P1/2CC (47)
Silevertinib
Lung Cancer
Black Diamond Therapeutics, Inc.P1/2CC (47)
Showing 2601 to 2625 of 6,305 assets
PreviousPage 105 of 253Next